JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

Search

MannKind Corp

Закрыт

СекторЗдравоохранение

3.51 2.93

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.51

Макс.

3.54

Ключевые показатели

By Trading Economics

Доход

5.7M

13M

Продажи

1.6M

78M

P/E

Средняя по отрасли

39.2

34.393

Рентабельность продаж

16.793

Сотрудники

403

EBITDA

8.3M

27M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+163.92% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

6 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-316M

1.2B

Предыдущая цена открытия

0.58

Предыдущая цена закрытия

3.51

Новостные настроения

By Acuity

14%

86%

21 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

MannKind Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

8 авг. 2025 г., 21:43 UTC

Отчет

Constellation Software 2Q Revenue Rises, Profit Shrinks

8 авг. 2025 г., 16:39 UTC

Приобретения, слияния, поглощения

Vinci Faces Reduced Earnout Payments to ACS for Cobra IS Deal

8 авг. 2025 г., 22:42 UTC

Приобретения, слияния, поглощения

The Paramount Merger Was a Bad Deal for Old Shareholders. Buying the Stock Is a Good Bet for New Ones. -- Barrons.com

8 авг. 2025 г., 21:31 UTC

Обсуждения рынка
Отчет

Cautious Long-Term Outlook For Natural Diamond Prices -- Market Talk

8 авг. 2025 г., 21:00 UTC

Отчет

Constellation Software 2Q Rev $2.84B >CSU.T

8 авг. 2025 г., 21:00 UTC

Отчет

Constellation Software 2Q Net $56M >CSU.T

8 авг. 2025 г., 21:00 UTC

Отчет

Constellation Software 2Q EPS $2.66 >CSU.T

8 авг. 2025 г., 20:55 UTC

Обсуждения рынка

Ahead of Cisco's Earnings, Investors Should Expect Conservatism -- Market Talk

8 авг. 2025 г., 20:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

8 авг. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

8 авг. 2025 г., 20:35 UTC

Обсуждения рынка

Mexico's Industrial Production Seen Higher in June -- Market Talk

8 авг. 2025 г., 20:28 UTC

Отчет

MP Materials Stock Soars Even Higher on Earnings. The Future Looks Bright, Too. -- Barrons.com

8 авг. 2025 г., 20:28 UTC

Отчет

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8 авг. 2025 г., 20:20 UTC

Приобретения, слияния, поглощения

Boeing's Spirit AeroSystems Deal Gets U.K. Approval. It's Part of the Turnaround. -- Barrons.com

8 авг. 2025 г., 20:08 UTC

Отчет

Tredegar: Recent Decline in Orders, Which Is a Measure of Future Sales Volume, Is Due to Lower Demand for Aluminum Extrusions in U.S. and Customers Pausing Orders to Evaluate New Higher Tariff >TG

8 авг. 2025 г., 19:34 UTC

Обсуждения рынка

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 авг. 2025 г., 19:15 UTC

Обсуждения рынка

U.S. Natural Gas Futures Settle Under $3 -- Market Talk

8 авг. 2025 г., 19:13 UTC

Обсуждения рынка

Oil Futures End Volatile Week Lower -- Market Talk

8 авг. 2025 г., 18:21 UTC

Обсуждения рынка

Gold Gains for the Week as Tariffs Go Forward -- Market Talk

8 авг. 2025 г., 17:27 UTC

Отчет

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

8 авг. 2025 г., 17:09 UTC

Отчет

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8 авг. 2025 г., 17:03 UTC

Отчет

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8 авг. 2025 г., 16:20 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Health Care Roundup: Market Talk

8 авг. 2025 г., 16:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

8 авг. 2025 г., 15:53 UTC

Приобретения, слияния, поглощения

Vinci: New Provisions Will Have No Significant Impact on Vinci's Financial Statements

8 авг. 2025 г., 15:51 UTC

Приобретения, слияния, поглощения

Vinci, ACS Terminate Agreement Regarding Creation of Joint Venture in Renewable Energy

8 авг. 2025 г., 15:50 UTC

Приобретения, слияния, поглощения

Vinci to Pay EUR300M of That Sum to ACS Taking Into Account Payments Already Made

8 авг. 2025 г., 15:48 UTC

Приобретения, слияния, поглощения

Vinci, ACS Agreed to Fix Earn-Out Related to Cobra IS Developments in Renewable Energy at EUR380M Payable in Cash

8 авг. 2025 г., 15:47 UTC

Приобретения, слияния, поглощения

Vinci: Acquisition of Cobra IS Was Completed Dec. 31, 2021

8 авг. 2025 г., 15:46 UTC

Приобретения, слияния, поглощения

Vinci: Agreement Will Definitively Settle Certain Provisions Related to Acquisition of Cobra IS

Сравнение c конкурентами

Изменение цены

MannKind Corp Прогноз

Целевая цена

By TipRanks

163.92% рост

Прогноз на 12 месяцев

Средняя 9.29 USD  163.92%

Максимум 12 USD

Минимум 7 USD

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для MannKind Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

7 ratings

7

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

4.079 / 4.323Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

21 / 374Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.